CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naive patients with FLT3 mutated AML
- Citation:
- J Clin Oncol vol 29 (supplement) abstr TPS199
- Meeting Instance:
- ASCO 2011
- Year:
- 2011
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2567
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- R. M. Stone H. Dohner G. Ehninger M. Villeneuve T. Teasdale J. D. Virkus L. R. Bressler M. M. Seiler G. Marcucci R. A. Larson
- Networks:
- Study
- CALGB-10603
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: